Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test
NCT ID NCT06147037
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is safe, how it spreads in the body, and what dose might work best.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a radioactive drug (actinium-225 attached to a targeting antibody) that delivers radiation directly to cancer cells
What this could lead to
If it works, this could offer a new treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 70 participants, so safety and the right dose are still being figured out. The radioactive drug may cause side effects and may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
WITHDRAWNIrvine, California, 92618, United States
-
Research Site
RECRUITINGPalo Alto, California, 94304, United States
-
Research Site
NOT_YET_RECRUITINGSanta Monica, California, 90404, United States
-
Research Site
RECRUITINGChicago, Illinois, 60637, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02215, United States
-
Research Site
WITHDRAWNSt Louis, Missouri, 63110, United States
-
Research Site
RECRUITINGOmaha, Nebraska, 68130, United States
-
Research Site
RECRUITINGCleveland, Ohio, 44195, United States
-
Research Site
WITHDRAWNPittsburgh, Pennsylvania, 15237, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGSeattle, Washington, 98109, United States
-
Research Site
NOT_YET_RECRUITINGEdmonton, Alberta, T6G 1Z2, Canada
-
Research Site
RECRUITINGHalifax, Nova Scotia, B3H 2Y9, Canada
-
Research Site
RECRUITINGMontreal, Quebec, H2X 0A9, Canada
-
Research Site
RECRUITINGSherbrooke, Quebec, J1H 5N4, Canada